Natera (NTRA) Stock

AUSTIN, Texas,--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a worldwide leader in cell-free DNA and genetic testing, has revealed new findings from the randomized, Phase III CALGB (Alliance) / SWOG 80702 study. These results will be shared today, January 25, 2025, during a late-breaking oral presentation at the 2025 American Society of Clinical Oncology's Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, CA. This unique study looked into whether patients who tested positive for Signatera gain any advantages.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a worldwide leader in cell-free DNA and genetic testing, has announced the release of the first set of abstracts from various studies that will be presented at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium (ASCO GI) scheduled for January 23-25, 2025, in San Francisco, CA. New findings from the BESPOKE CRC study will be shared in an oral presentation on January 25.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a worldwide leader in cell-free DNA and genetic testing, has shared its early unaudited results for the fourth quarter and the entire year ending December 31, 2024. The company anticipates total revenues of around $472 million for the fourth quarter of 2024, which is a 52% rise from $311 million in the same quarter of 2023. For the full year 2024, total revenues are expected to be about $1.7 billion.

The 'Undercovered' Dozen series showcases 12 stocks that don't get much attention, providing various investment options and sparking conversations among investors. Ready Capital Corporation has introduced new senior notes with a 9% yield, but they may be risky because of recent dividend cuts and poor earnings-to-debt ratios. Alex Pitti believes AVITA Medical has great growth potential due to new product launches and expanding market opportunities, making it an attractive long-term investment.

Natera, a top company in cfDNA testing, has experienced significant growth and is close to making a profit, but its current market value seems too high. The company faces strong competition from others like Guardant Health and Quest Diagnostics, along with legal challenges that could be risky. While Natera's revenue is mainly boosted by its oncology division, especially the Signatera test, future growth might slow down as it approaches its total addressable market.

Natera (NTRA) has reached a key support level, making it a potentially strong stock choice based on technical analysis. The stock has also broken through the resistance at the 20-day moving average, indicating a positive trend in the short term.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a worldwide leader in cell-free DNA and genetic testing, has announced that its Prospera Lung test has fulfilled the coverage criteria set by the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostics Services (MolDX) Program for single lung transplant (SLT) recipients. This coverage is relevant for SLT patients undergoing monitoring. SLT patients account for about 20% of all lung transplants in the U.S.1, and their numbers are rising.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a worldwide leader in cell-free DNA and genetic testing, has announced that it will showcase new data on SignateraTM at the San Antonio Breast Cancer Symposium (SABCS) from December 10-13 in San Antonio, TX. Natera and its partners will present six abstracts in total. "We are excited to share this new information on Signatera at SABCS, highlighting our dedication to providing evidence of its clinical benefits for patients."

Guardant Health has achieved one of the largest verdicts for false advertising in history, marking an important win for colorectal cancer patients who may benefit from their product, Guardant Reveal™. A jury in California's U.S. District Court ruled unanimously in favor of Guardant Health in their lawsuit against Natera, which was accused of misleading oncologists to hinder competition. This decision highlights the significance of accurate information in the healthcare industry.